drugset / Trial / NCT02189811

Polio End-game Strategies - Poliovirus Type 2 Challenge Study

NCT02189811 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

Poliomyelitis eradication has entered its last phase with only three remaining endemic countries, of which Pakistan is one. There hasn't been a case of wild type poliovirus 2 since 1999, and no case of wild type poliovirus 3 since November 2012. However, paralytic polio resulting from circulating strains of Sabin poliovirus type 2 have become a challenge, and reported from several areas with low population immunity to polio, including in Pakistan. This study will provide data to National Immunization Authorities in order to make strategic decisions about their polio vaccination schedules in anticipation of the global tOPV to bOPV switch and will provide data on the proposed responses to type 2 poliovirus outbreaks.

Timeline

Start
2014-09
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject IPV Vaccine — —
Subject IPV2 Unknown — —
Subject bOPV Vaccine — —
Comparator trivalent oral poliovirus vaccine Vaccine — Oral

Indications